Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Beyondspring Inc (BYSI)

Beyondspring Inc (BYSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,499
  • Shares Outstanding, K 39,029
  • Annual Sales, $ 1,750 K
  • Annual Income, $ -21,030 K
  • 60-Month Beta 0.27
  • Price/Sales 52.83
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BYSI with:

Options Overview Details

View History
  • Implied Volatility 71.46% ( -227.73%)
  • Historical Volatility 58.12%
  • IV Percentile 10%
  • IV Rank 3.38%
  • IV High 1,271.31% on 12/08/23
  • IV Low 29.47% on 07/11/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 1,194
  • Open Int (30-Day) 1,262

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +24.21%
on 09/10/24
2.60 -9.23%
on 10/01/24
+0.39 (+19.80%)
since 09/06/24
3-Month
1.70 +39.23%
on 08/05/24
2.60 -9.23%
on 10/01/24
-0.09 (-3.67%)
since 07/05/24
52-Week
0.65 +261.19%
on 10/10/23
4.00 -41.00%
on 03/06/24
+1.62 (+219.35%)
since 10/06/23

Most Recent Stories

More News
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

NEW YORK, May 27, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical...

BYSI : 2.36 (-0.42%)
BeyondSpring, Inc. (BYSI) Q4 2021 Earnings Call Transcript

BYSI earnings call for the period ending March 31, 2022.

BYSI : 2.36 (-0.42%)
BeyondSpring Files 2021 Annual Report on Form 20-F

NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global...

BYSI : 2.36 (-0.42%)
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

- Company to host call today, April 14, 2022 at 8:00 am ET - Conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or...

BYSI : 2.36 (-0.42%)
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company...

BYSI : 2.36 (-0.42%)
BeyondSpring Announces Organizational Streamlining

Resources to be Focused on Highest Value Business Activities 35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability NEW...

BYSI : 2.36 (-0.42%)
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and...

BYSI : 2.36 (-0.42%)
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

Adding plinabulin to a myelosuppressive chemotherapy regimen rapidly reversed (within 24 hours) chemotherapy-induced neutropenia and leukopenia in the...

BYSI : 2.36 (-0.42%)
BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

The two posters will be presented on Friday, December 10, 2021 8:00 AM to 9:30 AM EST NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring...

BYSI : 2.36 (-0.42%)
BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the...

BYSI : 2.36 (-0.42%)

Business Summary

BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced...

See More

Key Turning Points

3rd Resistance Point 2.66
2nd Resistance Point 2.55
1st Resistance Point 2.46
Last Price 2.36
1st Support Level 2.26
2nd Support Level 2.16
3rd Support Level 2.07

See More

52-Week High 4.00
Fibonacci 61.8% 2.72
Last Price 2.36
Fibonacci 50% 2.33
Fibonacci 38.2% 1.93
52-Week Low 0.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar